Literature DB >> 11137262

A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants.

M English1, J M MacLennan, J M Bowen-Morris, J Deeks, M Boardman, K Brown, S Smith, J Buttery, J Clarke, S Quataert, S Lockhart, E R Moxon.   

Abstract

A double-blind, randomised, controlled trial was conducted in 248 British infants to assess the immunogenicity and tolerability of three doses of a meningococcal group C/CRM (197) conjugate vaccine (Lederle Laboratories, USA) given at 2, 3 and 4 months. Control children received three doses of Hepatitis B vaccine (Engerix B(R); SmithKline Beecham). At 5 months of age, 100% of children receiving the conjugate vaccine had specific immunoglobulin G concentrations >2.0 microg/ml (n=116) compared with only 4% of control children (n=121). Those receiving the conjugate also had 2.5- and 1.6-fold higher geometric mean concentrations of PRP and diphtheria antibodies, respectively. The vaccine was well tolerated.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11137262     DOI： 10.1016/s0264-410x(00)00241-3

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 2.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

3.  Safety of a new conjugate meningococcal C vaccine in infants.

Authors:  R Lakshman; I Jones; D Walker; K McMurtrie; L Shaw; G Race; S Choo; L Danzig; P Oster; A Finn
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

4.  Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?

Authors:  Theodore F Tsai; Ray Borrow; Hanspeter E Gnehm; Bernard Vaudaux; Ulrich Heininger; Daniel Desgrandchamps; Christoph Aebi; Paul Balmer; Ronald D Pedersen; Bernard Fritzell; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2006-08

5.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 6.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 7.  Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

Authors:  Lisa K McNeil; Robert J Zagursky; Shuo L Lin; Ellen Murphy; Gary W Zlotnick; Susan K Hoiseth; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

8.  Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Authors:  Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

9.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.